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Abstract: OBJECTIVE: The management of brain tumour patients who would like to resume driving
is complex, and needs multidisciplinary input and a consensus among treating physicians. The Swiss
Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) aim to pro-
vide guidance on how to assess “fitness-to-drive” of glioblastoma patients and to harmonise the relevant
procedures in Switzerland. METHODS: At several meetings, Swiss neuro-oncologists discussed com-
mon practices on how to advise patients with a stable, i.e., non-progressive, glioblastoma, who wish to
resume driving after the initial standard tumour treatment. All participants of the SwissNOS meet-
ings were invited twice to return a questionnaire (modified Delphi process) on specific tools/procedures
they commonly use to assess “fitness-to-drive” of their patients. Answers were analysed to formulate
a tentative consensus for a structured and reasonable approach. RESULTS: Consensus on minimum
requirements for a “fitness-to-drive”programme for glioblastoma patients could be reached among Swiss
neuro-oncologists. The recommendations were based on existing guidelines and expert opinions regarding
patients with seizures, visual disturbances, cognitive impairment or focal deficits for safe driving. At this
point in time, the Swiss neuro-oncologists agreed on the following requirements for glioblastoma patients
after the initial standard therapy and without a seizure for at least 12 months: (1) stable cranial mag-
netic resonance imaging (MRI) according to Response Assessment in Neuro-Oncology (RANO) criteria,
to be repeated every 3 months; (2) thorough medical history, including current or new medication, a
comprehensive neurological examination at baseline (T0) and every 3 months thereafter, optionally an
electrocencephalogram (EEG) at baseline; (3) ophthalmological examination including visual acuity and
intact visual fields; and (4) optional neuropsychological assessment with a focus on safe driving. Test
results have to be compatible with safe driving at any time-point. Patients should be informed about
test results and optionally sign a document. CONCLUSIONS: We propose regular thorough clinical
neurological examination and brain MRI, optional EEG, neuropsychological and visual assessments to
confirm “fitness-to-drive” for glioblastoma patients after initial tumour-directed therapy. The proposed
“fitness-to-drive” assessments for glioblastoma patients serves as the basis for a prospective Swiss Pilot
Project GLIODRIVE (BASEC ProjectID 2020-00365) to test feasibility, adherence and safety in a struc-
tured manner for patients who wish to resume driving. Research will focus on confirming the usefulness
of the proposed tools in predicting “fitness-to-drive” and match results with events obtained from the
road traffic registry (Strassenverkehrsamt).
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Summary
OBJECTIVE: The management of brain tumour patients
who would like to resume driving is complex, and needs
multidisciplinary input and a consensus among treating
physicians. The Swiss Neuro-Oncology Society (Swiss-
NOS) and the Swiss Society for Legal Medicine (SGRM)
aim to provide guidance on how to assess “fitness-to-dri-
ve” of glioblastoma patients and to harmonise the relevant
procedures in Switzerland.
METHODS: At several meetings, Swiss neuro-oncologists
discussed common practices on how to advise patients
with a stable, i.e., non-progressive, glioblastoma, who
wish to resume driving after the initial standard tumour
treatment. All participants of the SwissNOS meetings were
invited twice to return a questionnaire (modified Delphi
process) on specific tools/procedures they commonly use
to assess “fitness-to-drive” of their patients. Answers were
analysed to formulate a tentative consensus for a struc-
tured and reasonable approach.
RESULTS: Consensus on minimum requirements for a
“fitness-to-drive”programme for glioblastoma patients
could be reached among Swiss neuro-oncologists. The
recommendations were based on existing guidelines and
expert opinions regarding patients with seizures, visual
disturbances, cognitive impairment or focal deficits for
safe driving. At this point in time, the Swiss neuro-oncol-
ogists agreed on the following requirements for glioblas-
toma patients after the initial standard therapy and without
a seizure for at least 12 months: (1) stable cranial mag-
netic resonance imaging (MRI) according to Response
Assessment in Neuro-Oncology (RANO) criteria, to be
repeated every 3 months; (2) thorough medical history, in-
cluding current or new medication, a comprehensive neu-
rological examination at baseline (T0) and every 3 months
thereafter, optionally an electrocencephalogram (EEG) at
baseline; (3) ophthalmological examination including visu-
al acuity and intact visual fields; and (4) optional neuropsy-
chological assessment with a focus on safe driving. Test
results have to be compatible with safe driving at any time-
point. Patients should be informed about test results and
optionally sign a document.
CONCLUSIONS: We propose regular thorough clinical
neurological examination and brain MRI, optional EEG,
neuropsychological and visual assessments to confirm “fit-
ness-to-drive” for glioblastoma patients after initial tumour-
directed therapy. The proposed “fitness-to-drive” assess-
ments for glioblastoma patients serves as the basis for a
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prospective Swiss Pilot Project GLIODRIVE (BASEC Pro-
jectID 2020-00365) to test feasibility, adherence and safe-
ty in a structured manner for patients who wish to resume
driving. Research will focus on confirming the usefulness
of the proposed tools in predicting “fitness-to-drive” and
match results with events obtained from the road traffic
registry (Strassenverkehrsamt).
Introduction
In Switzerland, as in many European countries, there is no
specific standard procedure for assessing “fitness-to-drive”
of brain tumour patients. Brain tumour patients do not have
to be reported to a Swiss Road Traffic Office (Strassen-
verkehrsamt, STVA) unless a physician considers them to
be medically “unfit-to-drive” and not adhering to the ad-
vice to abstain from driving, or in the event of a traffic ac-
cident reported to the STVA. According to the Swiss Road
Traffic Act (Strassenverkehrsgesetz, SVG, Loi fédérale sur
la circulation routière, Legge federale sulla circolazione
stradale) article 15, there is an explicit reporting right of
the treating physician. Furthermore, the Swiss Road Traffic
Act, articles 26 and 31, requires each road user to take per-
sonal responsibility.
The task of determining medical “fitness-to-drive” in pa-
tients with deficits caused by brain tumours falls primarily
on the treating physician, although few have been formally
trained in this area. Swiss guidelines exist for patients with
seizures [1], which is an immediate reason for driving
cessation. There are Swiss guidelines for other conditions
that increase the risk for traffic accidents, such as visual
impairments (minimum requirements are defined in the
Verkehrszulassungsverordnung, VZV) [2] and daytime
sleepiness [3], among others. Updated guidelines can be




Cognitive requirements are mentioned in various parts of
the Road Traffic Act (SVG), the Traffic Regulation
(Verkehrsregelverordnung, VRV) and the Traffic Licens-
ing Ordinance (Verkehrszulassungsverordnung, VZV),
which describe minimum medical requirements for safe
driving. However, they define the issue of neurocognition
rather vaguely.
The Traffic Licensing Ordinance (VZV) lists 10 minimum
medical requirements for “fitness-to-drive”, which are di-
vided by areas of function (vision, psyche, cognition), and
disease (neurological, cardiovascular and metabolic dis-
eases, diseases of the respiratory and abdominal organs,
diseases of the spinal column and the musculoskeletal sys-
tem). A further requirement relates to centrally acting sub-
stances (recreational drugs, medicines). Hearing perfor-
mance is no longer a criterion for “fitness-to-drive”.
Brain tumours may cause, among others, visual changes,
motor and sensory deficits, headaches, malfunctioning of
neurocognitive domains including delayed reaction time,
attention deficits and seizures – all of which can impair a
patient’s ability to drive safely. In daily practice, there is a
paucity of published data on which to provide comprehen-
sive evidence-based recommendations on when and how
to intervene when patients with a brain tumour wish to re-
sume driving.
To address this situation, 22 members of the interdisci-
plinary Swiss Neuro-Oncology Society (SwissNOS), one
traffic physician and representative of the Swiss Society
of Legal Medicine with Level 4 qualification (Institute
of Legal Medicine, Zurich) and an electrocencephalogram
(EEG) specialist were invited to participate in a modified
Delphi process in April and in August 2020. The aim was
to shed light on procedures used in daily practice and to
agree on minimum requirements to determine “fitness-to-
drive” for brain tumour patients in Switzerland. Glioblas-
toma, the most common and aggressive brain tumour, was
selected in a first step as an appropriate candidate tumour
that allows to study a relatively homogeneous brain tumour
subtype with standardized intial care, a relatively uniform
prognosis and a lower incidence of seizures than lower
grade gliomas [4, 5]. Standard treatment of newly diag-
nosed glioblastoma consists of maximum safe resection,
followed by chemo-radiotherapy for 3–6 weeks (depend-
ing on the age of the patient) and maintenance chemother-
apy for 6 months [6, 7]. Median survival with current treat-
ment is expected to be between 15 and 24 months, with
deviations in both directions depending on molecular char-
acteristics of the tumour [8]. Hereafter we refer to driving
a car or motorcycle for personal purposes and exclude pro-
fessional driving of, for example, trucks, buses or taxis.
Methods
At several meetings in 2019 and 2020, Swiss neuro-oncol-
ogists discussed common practices on how to advise pa-
tients with a stable (non-progressive) glioblastoma, who
wish to resume driving after initial standard tumour treat-
ment.
In a first step, a questionnaire with three inaugural ques-
tions and seven statements pertaining to “fitness-to-drive”
for glioblastoma patients was distributed to 22 Swiss neu-
ro-oncologists from all parts of Switzerland (fig. 1) and
from different disciplines, encompassing neurologists (n
= 10), neurosurgeons (n = 7), radiation oncologists (n =
2), medical oncologists (n = 3) and one traffic physician.
Two neuropsychologists experienced in assessing “fitness-
to-drive” proposed a standardised test battery covering the
following domains: basic processing speed, attention, vi-
suo-spatial perception, attention and executive functions.
Furthermore, semi-standardised questions aimed at assess-
ing driving experience, as well as possible behavioural
and personality-related aspects (impulsiveness, risk behav-
iour, etc.). One EEG specialist was specifically questioned
about the value of EEG to predict “fitness-to-drive”. Mem-
bers of the Swiss Society for Legal Medicine (SGRM)
were invited to comment on the procedures.
The following assessments considered to be useful to as-
sess “fitness-to-drive“ were proposed in the survey,
grouped into four main categories: (1) cranial magnetic
resonance imaging (cMRI) at baseline (T0) and in the fol-
low-up period; (2) clinical neurological examination, in-
cluding a thorough history and an EEG at baseline, i.e.,
once prior to resuming driving (T0); (3) vision and (4) neu-
ropsychological assessments focussing on driving capaci-
ties, both at baseline.
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The seven statements of the modified Delphi survey read
as follows:
1. Do you even consider patients after initial standard
therapy for their glioblastoma and not experiencing
any seizure for at least 12 months, who wish to resume




5. Which assessments do you consider as minimal re-
quirements for “fitness-to-drive”?
– Comprehensive neurological examination and his-
tory, EEG at baseline (T0)
– cMRI at T0
– Visual fields and visual acuity at T0
– Neuropsychological assessment with focus on safe
driving at T0
10. Which findings in your opinion are incompatible with
driving?
– Neurological deficits such as: palsies, sensory
deficits, neglect and others that impair safe driving
– EEG with epilepsy-specific potentials
– Progressive disease on cMRI according to Re-
sponse Assessment in Neuro-Oncology (RANO)
criteria [9]
– Visual fields: any anopsy, according to the regula-
tions of the Federal Roads Office (FEDRO).
– Neuropsychological assessments not compatible
with driving
– Unreliability of the patient
17. Question 4 offered a battery of neuropsychological
tests (with a focus on safe driving) to be selected.
18. Question 5 referred to the follow-up period.
For glioblastoma patients, who have resumed driving,
which minimum requirements do you consider in the
follow-up period and at which time-points?
– Follow-up every 3 months or other intervals?
– Thorough history, neurological examinations?
– cMRI. Further tests as indicated by symptoms?
Figure 1: Sites of the SwissNOS panellists.
– Questionnaire on driving habits and events?
23. Do you agree that every patient has to sign a document
with the recommendations of his treating physician?
– Yes
– No
26. Do you agree that every patient who does not adhere
to the recommendation has to be reported to the Road
Traffic Office (SVG, article 15)?
– Yes
– No
– If answered “No”, additional question: Why not?
In a further step, statements were compiled to frame a ten-
tative Swiss guideline for glioblastoma patients, who wish
to resume driving after completion of the initial standard
treatment. In a last step, responses were compared with na-
tional and international recommendations for the respec-
tive items.
Results
The first question of the survey on whether the treating
physician would even consider “fitness-to-drive” assess-
ments in a brain tumour patient was uniformly answered
with yes. The question of an upper age limit or restrictions
to certain type of roads was mainly denied (fig. 2).
Tools that were considered necessary to assess “fitness-to-
drive” after standard treatment of a glioblastoma are com-
piled in table 1. Consensus could be reached for a thorough
history and neurological examinations at baseline and at
each follow-up visit.
A baseline EEG without any history or clinical evidence of
epilepsy was supported by two thirds of the respondents.
There was consensus on baseline and regular follow-up
imaging. Visual field examinations were considered by one
third of the panellists as part of a thorough neurological ex-
amination and not in need of a specialist (i.e., an ophthal-
mologist). The same holds true for a neuropsychological
assessment (table 1).
Criteria incompatible with driving for glioblastoma pa-
tients were discussed inconsistently among the panellists
and are presented in table 2. Consensus could be reached
for neurological deficits incompatible with driving, such
as non-compensated palsies, neglect, altered consciousness
Table 1: Tools proposed to assess “fitness-to-drive”.
Tools Panellists (n =
23)
Thorough history and neurological examination at
T0 and in follow-up
23 yes, 0 no
EEG at T0 17 yes, 7* no
Cranial MRI at T0 22 yes, 1 no
Cranial MRI every 3 months during follow-up 23 yes, 0 no
Visual fields and visual acuity at T0 16 yes, 7 no†
Neuropsychology at T0‡ 14 yes, 9 no
EEG = electrocencephalogram; MRI = magnetic resonance imaging;
T0 = baseline, i.e., prior to resuming driving. *An EEG specialist was
consulted for the EEG-specific question, therefore 24 panellists an-
swered this question. † Panellists who voted “no” declared this assess-
ment to be part of a thorough neurological examination without the
need of a specialist. ‡ Neuropsychological tests with focus on “fitness-
to-drive” as proposed by the two neuropsychologists
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Figure 2: Inaugural questions. Proportion of agreement, panellists n = 23.
Table 2: Criteria considered incompatible with driving.
Criteria Panellists ( n =
23)
Palsies, sensory disorders affecting driving, ne-
glect, etc.
23 yes
Epilepsy-specific potentials 19 yes, 5* no
Cranial MRI; progressive disease (RANO) 23 yes
Vision: any anopsy 23 yes
Neuropsychology: attention deficits, neglect, etc.
according to reccomendations of neuropsychologist
21 yes, 2 no
Unreliability of patient 18 yes, 5 no
EEG = electrocencephalogram; MRI = magnetic resonance imaging.
RANO = Response Assessment in Neuro-Oncology. *An EEG special-
ist was consulted for the EEG-specific question, therefore 24 panellists
answered to this question.
and any visual field deficits. Epilepsy-specific potentials
on EEG were considered as a contraindication to drive by
18 out of 24 panellists. The ones who voted against this
statement asked for a more nuanced evaluation. Unreliabil-
ity of a patient in terms of not adhering to the physician’s
advice such as taking antiepileptic drugs, was considered
by only 18 out of 23 panellists as incompatible with “fit-
ness-to-drive”
There were some comments from the panellists outside the
Delphi questionnaire, mainly dealing with medication such
as opioids and adherence to antiepileptic drug treatment.
It was a strong wish of most panellists to harmonise the
procedure for “fitness-to- drive” in Switzerland for all
brain tumour patients and for patients with brain metas-
tases.
It was well accepted that, following the investigations
deemed necessary, a lead physician, usually a neurologist,
who coordinates the tests, has to communicate the results
to the patient and decisions on “fitness-to-drive” have to be
documented in the patient’s file. Whether the patient has to
sign a document remains controversial. The proposed fol-
low-up examinations every 3 months in glioblastoma pa-
tients were unanimously accepted by the panellists.
Discussion
Swiss guidelines exist for epilepsy and driving: “Fahreig-
nung mit Epilepsie” [1] issued by the Verkehrskommission
der Schweizerischen Liga gegen Epilepsie (Ligue Suisse
contre l’Epilepsie, Lega Svizzera contro l’Epilessia., SLE).
These guidelines also apply to brain tumour patients ex-
periencing seizures. Repeat EEG recordings are clearly in-
dicated in glioblastoma patients with a first symptomatic
seizure, but this is not the case in seizure-free patients.
Since these patients do not suffer from epilepsy according
to the current ILAE (International League Against Epilep-
sy) diagnostic criteria (www.ilae.org/files/ilaeGuideline/
Definition2014.pdf) the recommendations of the SLE do
not apply and should not be applied. When an EEG is
recorded in these patients, there is the possibility that it
will show epileptiform discharges in the absence of clinical
signs of epilepsy. At this point, neuro-oncologists have
to decide whether they would declare the patient with a
glioblastoma “fit -to-drive” despite the EEG abnormalities.
This question is not answered by scientific evidence.
Requirements regarding vision and driving are regulated
by law (Strassenverkehrsgesetz, SVG, Verordnung über
die Zulassung von Personen und Fahrzeugen zum
Strassenverkehr “Verkehrszulassungsverordnung”, VZV,
Bundesamt für Strassen, ASTRA).
In contrast, there are no specific guidelines for brain tu-
mour patients and driving in Switzerland. Internationally,
there are a few guidelines for brain tumour patients and
their treating physicians to guide “fitness-to-drive”.
In the UK, for instance, patients are not allowed to drive
for 1 year after treatment of a World Health Organization
(WHO) grade 1 or 2 glioma. The situation is usually re-
assessed after 1 year. The patients get their licence back
as long as they are not having seizures or any disability
that affects their ability to drive https://www.cancerre-
searchuk.org/about-cancer/brain-tumours/living-with/dri-
ving. However, in the UK, a patient with a WHO grade 3
glioma or a glioblastoma (WHO grade 4) is not allowed to
drive for 2 years after initial treatment. This usually means
2 years after 9 months of initial standard therapy. Most
glioblastoma patients in the UK, therefore, will never have
the chance to resume driving. It is common for the Driver
and Vehicle Licensing Agency (DVLA) to ask people with
a brain tumour to surrender their licence. The return of this
document is not by default, but the treating specialist is
contacted, and decisions are made on an individual basis. If
patients get their licence back, it may only be valid for a
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Figure 3: GLIODRIVE Project (BASEC ID 2020-00365).
short period and the doctor's consent will be necessary for
renewal.
German colleagues are guided by the “Begutach-
tungsleitlinien zur Kraftfahreignung”, a document regular-
ly updated, revised and published online after approval by
the Federal Ministry for Transport and Digital Infrastruc-
ture (www.bast.de). The German guidelines are a compila-
tion of physical and/or mental handicaps that make people
unable to drive or limit their driving ability. These guide-
lines are intended to ease the case-by-case evaluation of
“fitness-to-drive” and serve as a reference tool for eval-
uators who have to judge driving licence applicants or
holders with regard to their ability to drive. However, the
57-page document has no chapter devoted specifically to
brain tumour patients.
Recently, Valencia-Sanchez et al. from the Mayo Clinic,
Phoenix AZ, published their clinical evaluation of “fitness-
to-drive” in patients with brain metastases [10]. The au-
thors prospectively evaluated the concordance between
neurology assessments in 41 individuals with brain metas-
tases. The evaluation included an interview and neurolog-
ical examination. Participants subsequently underwent an
“occupational therapy driving assessment” during which a
battery of objective measures of visual, cognitive, and mo-
tor skills related to driving was administered. There was
poor association between the assessment by neurologists
and the outcome of the test battery. The authors concluded
that subtle deficits, which might impair the ability to dri-
ve safely, may not be evident on neurological examination
alone and strongly recommend objective measures.
Conclusion
In order to obtain more evidence on whether and which
assessments are complementary to increase road safety
for brain tumour patients, we are currently conducting a
prospective observational study with a cohort of glioblas-
toma patients who wish to resume driving after initial stan-
dard treatment (GLIODRIVE project design, fig. 3). First
and foremost, it is worthwhile to plan the order of assess-
ments according to minimum medical requirements and
exclusion criteria, and to avoid unnecessary cost and bur-
den for the patient. Four main test categories will be stud-
ied at baseline and compared with each other: (1) imaging
(cMRI); (2) neurological examination, including a thor-
ough history and an EEG; (3) examination of visual fields
and acuity; and (4) neuropsychological evaluation fo-
cussing on safe driving. The research aims to confirm the
feasibility of the proposed tools in daily practice and to
compare outcome of the respective instruments in pre-
dicting “fitness-to-drive”, as well as matching results with
events obtained from the Road Traffic Registry (Strassen-
verkehrsamt). An additional question of the study will be
whether the patient's self-assessment correlates with events
on the street.
Provided that the study results prove useful, the concept
can be expanded to other types of brain tumours and pa-
tients with brain metastases, preferably again in the context
of an observational study.
In anticipation of study results, we propose tentative as-
sessments that are currently agreed on by the SwissNOS
panellists, in red with a consensus, in blue considered op-
tional (fig. 4).
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Figure 4: Proposed assessments for “fitness-to-drive” for glioblastoma patients.
Disclosure statement
There are no funding sources for this initiative. The authors declare
that there are no conflicts of interest regarding the content of this paper.
Authorship acknowledgments
Conception of the two Delphi surveys: HS
SwissNOS members participating in the Delphi surveys: HS, IL, RU,
HG, HT, HC, LRE, VF, CD, NM, HA, MD, BB, LH, GD, RM, PGF,
SP, WT, WHG, WF, RP, WM and Karl F. Kothbauer, Lucerne (de-
ceased)
Swiss Society for Legal Medicine: KK
Conception and design of the GLIODRIVE Project: HS, LD, FI, RU,
EN, PT
References
1 Arnold P, Bonetti C, Mathis J, Meyer K, Seeck M, Seeger R, et al.
Fahreignung mit Epilepsie. Swiss Med Forum. 2019;19(4546):737–40.
doi: http://dx.doi.org/10.4414/smf.2019.08402.
2 Mérour A, Favrat B, Borruat F-X, Pasche C. [Requirements on vision
for driving: to see more clearly]. Rev Med Suisse.
2014;10(452):2252–4, 2256–7. [Article in French.] PubMed.
3 Mathis J, Kohler M, Hemmeter UM, Seeger R. Verkehrskommission
Schweizerische Gesellschaft für Schlafforschung, Schlafmedizin und
Chronobiologie (SGSSC). Fahreignung bei Schläfrigkei. Swiss Med Fo-
rum. 2017;17(20):442–7. doi:
4 van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with
brain tumours: epidemiology, mechanisms, and management. Lancet
Neurol. 2007;6(5):421–30. doi: http://dx.doi.org/10.1016/
S1474-4422(07)70103-5. PubMed.
5 Skardelly M, Brendle E, Noell S, Behling F, Wuttke TV, Schittenhelm J,
et al. Predictors of preoperative and early postoperative seizures in pa-
tients with intra-axial primary and metastatic brain tumors: A retrospec-
tive observational single center study. Ann Neurol. 2015;78(6):917–28.
doi: http://dx.doi.org/10.1002/ana.24522. PubMed.
6 Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G,
et al. EANO guidelines on the diagnosis and treatment of diffuse
gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–86. doi:
http://dx.doi.org/10.1038/s41571-020-00447-z. PubMed.
7 Roth P, Hottinger AF, Hundsberger T, Läubli H, Schucht P, Reinert M,
et al. A contemporary perspective on the diagnosis and treatment of dif-
fuse gliomas in adults. Swiss Med Wkly. 2020;150:w20256 .
http://dx.doi.org/10.4414/smw.2020.20256. PubMed.
8 Gramatzki D, Roth P, Rushing EJ, Weller J, Andratschke N, Hofer S, et
al. Bevacizumab may improve quality of life, but not overall survival in
glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431–6.
doi: http://dx.doi.org/10.1093/annonc/mdy106. PubMed.
9 Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG,
Galanis E, et al. Updated response assessment criteria for high-grade
gliomas: response assessment in neuro-oncology working group. J Clin
Oncol. 2010;28(11):1963–72. doi: http://dx.doi.org/10.1200/
JCO.2009.26.3541. PubMed.
10 Valencia-Sanchez C, Gorelkin VC, Mrugala MM, Sharma A, Vora SA,
Ashman JB, et al. Clinical evaluation of fitness to drive in patients with
brain metastases. Neurooncol Pract. 2019;6(6):484–9. doi:
http://dx.doi.org/10.1093/nop/npz027. PubMed.
Original article Swiss Med Wkly. 2021;151:w20501
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 6
